Iridex Corporation filings document an ophthalmic medical technology issuer whose disclosures center on laser systems, delivery devices, consumables, and procedure probes for glaucoma and retinal disease applications. Form 8-K reports furnish operating and financial results, preliminary results, Regulation FD investor materials, material agreements, and other material-event disclosures.
Proxy materials describe board matters, executive compensation, equity award valuation adjustments, and pay-versus-performance information. The filing record also includes Nasdaq continued-listing compliance updates, capital-structure context such as stockholders’ equity requirements, exhibits to press releases and presentations, and Inline XBRL cover-page data for formal Exchange Act reporting.
IRIDEX CORP Chief Financial Officer Romeo R. Dizon reported a tax-related share withholding. On this Form 4, 2,691 shares of Common Stock were disposed of at $1.12 per share to satisfy a tax obligation, classified as a tax-withholding disposition rather than an open-market sale. After this transaction, he directly holds 133,284 shares of IRIDEX CORP Common Stock.
IRIDEX CORP President and CEO Patrick Mercer reported a tax-withholding disposition of 3,990 shares of Common Stock at $1.12 per share. This transaction satisfied tax obligations by delivering shares rather than through an open-market sale. After the transaction, he directly holds 368,784 shares.
IRIDEX CORP Chief Financial Officer buys additional shares on the open market. On this Form 4, Romeo R. Dizon reported purchasing 975 shares of IRIDEX common stock in an open-market transaction at an average price of $1.1386 per share. Following this buy, he directly owns 135,975 common shares.
IRIDEX CORP’s Chief Financial Officer, Romeo R. Dizon, reported an open-market purchase of company stock. On June 11, 2026, he bought 1,675 shares of IRIDEX common stock at $1.14 per share. Following this transaction, he directly owns 135,000 common shares, indicating a modest increase to his existing position.
IRIDEX CORP’s Chief Financial Officer Romeo R. Dizon reported an open-market purchase of 2,400 shares of common stock at about $1.12 per share. After this transaction, he directly holds 133,325 shares. This is a relatively small, routine insider buy that modestly increases his direct ownership.
IRIDEX Corp's Chief Financial Officer, Romeo R. Dizon, bought additional company stock in the open market. He purchased 2,521 shares of Common Stock at a price of $1.15 per share. Following this transaction, he directly holds 130,925 shares, increasing his personal stake in the company.
IRIDEX CORP Chief Financial Officer Romeo R. Dizon bought additional company stock in the open market. He purchased 2,400 shares of common stock at a price of $1.17 per share. After this transaction, he directly owns a total of 128,404 IRIDEX common shares.
IRIDEX CORP President and CEO Patrick Mercer reported a tax-related share disposition on Common Stock. On this Form 4, 19,233 shares were delivered at $1.01 per share to cover tax obligations, and he now directly holds 372,774 shares of Common Stock.
IRIDEX Corp Chief Financial Officer Romeo R. Dizon reported an open-market purchase of 5,004 shares of common stock at $1.00 per share. Following this transaction, he directly holds 126,004 shares of IRIDEX common stock, modestly increasing his personal stake in the company.
IRIDEX Corporation reported a smaller quarterly loss on essentially flat revenue. For the three months ended April 4, 2026, revenue was $11.8 million versus $11.9 million a year earlier, as higher glaucoma and "other" sales offset lower retina product revenue.
Gross profit declined to $4.7 million and gross margin slipped to 40.2% from 42.5%, mainly from higher manufacturing and tariff-related costs during a transition to lower-cost contract manufacturers. Operating expenses fell slightly, with general and administrative costs down due to lower consulting and deal-related legal spending.
Net loss improved to $0.5 million from $1.7 million, helped by the absence of the prior-year $1.3 million loss on extinguishment of a convertible note. Cash and cash equivalents were $4.6 million and working capital was $11.8 million at quarter end. Management believes existing liquidity is sufficient for at least the next 12 months.